Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the β-cell potassium adenosine triphosphate channel

被引:71
|
作者
Gloyn, AL
Cummings, EA
Edghill, EL
Harries, LW
Scott, R
Costa, T
Temple, IK
Hattersley, AT
Ellard, S
机构
[1] Peninsula Med Sch, Exeter EX2 5AX, Devon, England
[2] Dalhousie Univ, Dept Pediat, Halifax, NS B3K 6R8, Canada
[3] IWK Hlth Ctr, Halifax, NS B3K 6R8, Canada
[4] Univ Montreal, Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada
[5] Univ Southampton, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England
[6] Univ Southampton, Div Human Genet, Southampton SO16 5YA, Hants, England
[7] Hosp Natl Hlth Serv Trust, Southampton SO16 5YA, Hants, England
来源
关键词
D O I
10.1210/jc.2004-0568
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Activating mutations in the KCNJ11 gene encoding for the Kir6.2 subunit of the beta-cell ATP-sensitive potassium channel have recently been shown to be a common cause of permanent neonatal diabetes. In 80% of probands, these are isolated cases resulting from de novo mutations. We describe a family in which two affected paternal half-siblings were found to be heterozygous for the previously reported R201C mutation. Direct sequencing of leukocyte DNA showed that their clinically unaffected mothers and father were genotypically normal. Quantitative real-time PCR analysis of the father's leukocyte DNA detected no trace of mutant DNA. These results are consistent with the father being a mosaic for the mutation, which is restricted to his germline. This is the first report of germline mosaicism in any form of monogenic diabetes. The high percentage of permanent neonatal diabetes cases due to de novo KCNJ11 mutations suggests that germline mosaicism maybe common. The possibility of germline mosaicism should be considered when counseling recurrence risks for the parents of a child with an apparently de novo KCNJ11 activating mutation.
引用
收藏
页码:3932 / 3935
页数:4
相关论文
共 44 条
  • [21] Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene
    Tonini, G.
    Bizzarri, C.
    Bonfanti, R.
    Vanelli, M.
    Cerutti, F.
    Faleschini, E.
    Meschi, F.
    Prisco, F.
    Ciacco, E.
    Cappa, M.
    Torelli, C.
    Cauvin, V.
    Tumini, S.
    Iafusco, D.
    Barbetti, F.
    DIABETOLOGIA, 2006, 49 (09) : 2210 - 2213
  • [22] Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation
    C. Colombo
    M. Delvecchio
    C. Zecchino
    M. F. Faienza
    L. Cavallo
    F. Barbetti
    Diabetologia, 2005, 48 : 2439 - 2441
  • [23] The E23K variant of KCNJ11 encoding the pancreatic β-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes
    Sesti, Giorgio
    Laratta, Emanuela
    Cardellini, Marina
    Andreozzi, Francesco
    Del Guerra, Silvia
    Irace, Concetta
    Gnasso, Agostino
    Grupillo, Maria
    Lauro, Renato
    Hribal, Marta Letizia
    Perticone, Francesco
    Marchetti, Piero
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06): : 2334 - 2339
  • [24] Infantile spasms as an epileptic feature of DEND syndrome associated with an activating mutation in the potassium adenosine triphosphate (ATP) channel, Kir6.2
    Bahi-Buisson, Nadia
    Eisermann, Monica
    Nivot, Sylvie
    Bellanne-Chantelot, Christine
    Dulac, Olivier
    Bach, Nathalie
    Plouin, Perrine
    Chiron, Catherine
    de Lonlay, Pascale
    JOURNAL OF CHILD NEUROLOGY, 2007, 22 (09) : 1147 - 1150
  • [25] Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encodiing Kir6.2
    Kim, Min Sun
    Kim, Sun-Young
    Kim, Gu-Hwan
    Yoo, Han Wook
    Lee, Dong Whan
    Lee, Dae-Yeol
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 (04) : 616 - 620
  • [26] Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2—initial and long-term response to sulfonylurea therapy
    Verena M. Wagner
    Britta Kremke
    Olaf Hiort
    Sarah E. Flanagan
    Ewan R. Pearson
    European Journal of Pediatrics, 2009, 168 : 359 - 361
  • [27] Sulfonylurea instead of insulin in PNDM patients with activating mutation in the gene KCNJ11 encoding the Kir6.2 subunit led to significant improvement of DM compensation (vol 7, pg 31, 2006)
    Paskova, M.
    Zofcakova, M.
    Stanik, J.
    Sumnik, Z.
    PEDIATRIC DIABETES, 2006, 7 (06) : 365 - 365
  • [28] The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy
    Koster, Joseph C.
    Cadario, Francesco
    Peruzzi, Cinzia
    Colombo, Carlo
    Nichols, Colin G.
    Barbetti, Fabrizio
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (03): : 1054 - 1061
  • [29] Severe congenital hyperinsulinism caused by a mutation in the Kir6.2 subunit of the adenosine triphosphate-sensitive potassium channel impairing trafficking and function
    Marthinet, E
    Bloc, A
    Oka, Y
    Tanizawa, Y
    Wehrle-Haller, B
    Bancila, V
    Dubuis, JM
    Philippe, J
    Schwitzgebel, VM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (09): : 5401 - 5406
  • [30] Multiple subtypes of diabetes are associated with activating mutations in KCNJ11, which encodes the Kir6.2 sub-unit of the beta-cell ATP sensitive potassium (KATP) channel
    Gloyn, AL
    Edghill, EL
    Pearson, ER
    Mackay, DJG
    Temple, IK
    Shield, JPH
    Noyes, K
    Freedenberg, D
    Gillespie, KM
    Lambert, AP
    Gale, EA
    Ellard, S
    Hattersley, AT
    DIABETOLOGIA, 2004, 47 : A82 - A83